Navigation Links
WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
Date:10/18/2007

SHANGHAI, China, Oct. 18 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been nominated the winner of Deloitte Technology Fast 50 China 2007, a ranking of the fastest growing technology companies in China as recognized by Deloitte Touche Tohmatsu (Deloitte).

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Deloitte Technology Fast 50 China program is an annual award program that ranks technology, media, and telecommunications companies located in Mainland China and Hong Kong. According to Deloitte, winners are selected based on their average revenue growth rates over the last three years. WuXi PharmaTech has been included on such a high-profile list for three consecutive years since Deloitte China launched this award program in 2005. Participants in the Deloitte Technology Fast 50 China program will automatically qualify for participation in the Deloitte Technology Fast 500 Asia Pacific 2007 program, which annually recognizes the 500 fastest growing technology companies in Asia Pacific. This will be the fourth consecutive year that WuXi PharmaTech wins such a prestigious award.

"We're honored to receive such a distinguished award once again in recognition of our ongoing success," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "The award reflects our consistent high operation standards and transparency, and tireless dedication to customer satisfaction. In 2007 we continued to expand service offering capabilities and capacities to offer more value-added and responsive services to our collaborative partners."

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
3. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
4. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
5. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
6. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
7. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
8. Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor
9. DNA purification from pig ears to bird blood using proven DNeasy Technology
10. Near Infrared Technology and Optical Agents For Molecular Imaging
11. Technology helps but the best way to reduce Sarbox cost is with people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):